<DOC>
	<DOCNO>NCT01483729</DOCNO>
	<brief_summary>This single dose , randomize , open-label , 6 sequence , 3-period , crossover study evaluate relative bioavailability danoprevir ritonavir healthy volunteer . In Part 1 , subject randomize receive single oral dos one three tablet formulation danoprevir plus reference ritonavir formulation , least 7-day washout period . In Part 2 , subject randomize receive single oral dos one three tablet formulation ritonavir plus reference formulation danoprevir , least 7-day washout betwen period . The anticipated time study 30 day .</brief_summary>
	<brief_title>A Relative Bioavailability Study Danoprevir Ritonavir Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Healthy volunteer , 18 45 year age inclusive Body mass index 18.0 32.0 kg/m2 , weight &gt; /= 50 kg Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Nonsmoker Medical history without major , recent ongoing pathology Females childbearing potential male female partner childbearing potential must agree use 2 form contraception ( barrier form plus intrauterine device spemicide ) study 90 day last drug administration Pregnant lactate woman male female partner pregnant lactate Positive result drug abuse screen prior admission clinical site study period Positive hepatitis B , hepatitis C HIV infection Use hormonal contraceptive ( birth control pill , injectable , implantable device ) within 30 day first dose study medication Routine use 2 g acetaminophen daily History clinically significant drug allergy ( anaphylaxis ) hepatotoxicity History hypersensitivity danoptevir , ritonavir , protease inhibitor History ( within 3 month screen ) alcohol consumption exceed 2 standard drink per day average Current enrollment participation clinical trial experimental medication medical device within 3 month screen unless agree upon Sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>